Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2022 Filed Sep 8, 2022 20:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $576.85 | $1,730.55 |
DisclosureSEC source: 0001883850-22-000064 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,679 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on September 6, 2022 at prices ranging from $576.84 to $576.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 6, 2022 at each separate price. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · derivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,479 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · derivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,479 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · derivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,410 | $622.06 | $877,104.60 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,682 F3 · price: Represents volume-weighted average price of sales of 1,410 shares of Company stock on August 4, 2022 at prices ranging from $622.00 to $622.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2022 at each separate price. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,479 | $380.95 | $944,375.05 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,156 | $621.54 | $2,583,120.24 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,613 F2 · price: Represents volume-weighted average price of sales of 4,156 shares of Company stock on August 4, 2022 at prices ranging from $621.00 to $621.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2022 at each separate price. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,361 | $374.12 | $1,631,537.32 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,887 | $620.85 | $3,034,093.95 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,408 F1 · price: Represents volume-weighted average price of sales of 4,887 shares of Company stock on August 4, 2022 at prices ranging from $620.16 to $620.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2022 at each separate price. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,613 | $482.68 | $1,743,922.84 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000054 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,682 Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $658.09 | $1,974.27 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,182 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $656.97 | $1,970.91 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,185 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $655.44 | $3,932.64 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,188 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on May 2, 2022 at prices ranging from $655.27 to $655.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $654.21 | $654.21 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,194 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 21 | $653.57 | $13,724.97 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,195 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 21 shares of Company stock on May 2, 2022 at prices ranging from $653.16 to $653.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $652.71 | $9,137.94 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,216 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on May 2, 2022 at prices ranging from $652.03 to $652.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $651.46 | $6,514.60 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,230 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on May 2, 2022 at prices ranging from $651.07 to $651.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $650.47 | $3,902.82 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,240 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on May 2, 2022 at prices ranging from $650.17 to $650.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $649.62 | $3,248.10 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,246 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on May 2, 2022 at prices ranging from $649.28 to $649.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $648.68 | $2,594.72 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,251 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on May 2, 2022 at prices ranging from $648.48 to $648.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $647.09 | $1,941.27 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,255 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on May 2, 2022 at prices ranging from $647.01 to $647.26. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $646.49 | $4,525.43 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,258 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on May 2, 2022 at prices ranging from $646.33 to $646.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $645.64 | $1,936.92 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,265 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $644.54 | $5,800.86 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on May 2, 2022 at prices ranging from $644.04 to $644.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| May 02, 2022 Filed May 3, 2022 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $643.76 | $3,218.80 |
DisclosureSEC source: 0001883850-22-000044 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,277 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on May 2, 2022 at prices ranging from $643.32 to $643.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 2, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $701.82 | $2,105.46 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,282 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $698.14 | $2,792.56 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,285 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2022 at prices ranging from $698.04 to $698.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $697.39 | $4,881.73 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,289 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on April 1, 2022 at prices ranging from $697.00 to $697.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $696.50 | $5,572.00 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,296 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on April 1, 2022 at prices ranging from $696.14 to $696.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $695.46 | $9,736.44 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,304 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on April 1, 2022 at prices ranging from $695.02 to $695.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $694.74 | $2,778.96 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,318 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2022 at prices ranging from $694.16 to $694.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $693.69 | $2,774.76 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,322 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on April 1, 2022 at prices ranging from $693.52 to $693.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $692.41 | $6,924.10 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,326 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on April 1, 2022 at prices ranging from $692.24 to $692.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10 | $691.34 | $6,913.40 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,336 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 10 shares of Company stock on April 1, 2022 at prices ranging from $691.15 to $691.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $690.59 | $8,287.08 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,346 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on April 1, 2022 at prices ranging from $690.01 to $690.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $689.42 | $2,068.26 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,358 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2022 at prices ranging from $689.17 to $689.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $688.59 | $8,263.08 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,361 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on April 1, 2022 at prices ranging from $688.23 to $688.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $687.45 | $2,062.35 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,373 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on April 1, 2022 at prices ranging from $687.00 to $687.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $686.83 | $4,120.98 |
DisclosureSEC source: 0001883850-22-000035 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,376 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on April 1, 2022 at prices ranging from $686.73 to $686.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 13 | $623.23 | $8,101.99 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 13 shares of Company stock on March 1, 2022 at prices ranging from $623.00 to $623.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 21 | $622.49 | $13,072.29 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,395 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 21 shares of Company stock on March 1, 2022 at prices ranging from $622.01 to $622.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $621.43 | $4,971.44 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,416 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on March 1, 2022 at prices ranging from $621.36 to $621.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $620.55 | $3,723.30 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,424 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on March 1, 2022 at prices ranging from $620.11 to $620.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $619.40 | $4,335.80 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,430 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on March 1, 2022 at prices ranging from $619.07 to $619.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $618.34 | $1,855.02 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,437 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 1, 2022 at prices ranging from $618.24 to $618.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9 | $617.66 | $5,558.94 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,440 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 9 shares of Company stock on March 1, 2022 at prices ranging from $617.16 to $617.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $616.55 | $4,315.85 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,449 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on March 1, 2022 at prices ranging from $616.18 to $616.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $615.45 | $1,846.35 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,456 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on March 1, 2022 at prices ranging from $615.39 to $615.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:19 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $614.38 | $2,457.52 |
DisclosureSEC source: 0001883850-22-000018 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,459 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on March 1, 2022 at prices ranging from $614.10 to $614.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 1, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.